Two studies have shown that Aurora kinase A/B inhibition is synthetically lethal with RB1 deficiency in breast cancer and small-cell lung cancer cell lines [62,63], suggesting alternative therapeutic strategies for RB1-null tumors or new combinatorial strategies to prevent acquired resistances to CDK4/6 inhibitors [57]. This evidence concerns the gene RB1 and breast carcinoma.